Idorsia Gains Ground as DEA Proposes Reclassifying DORAs from Schedule IV to Schedule V

A DEA proposed rulemaking to move dual orexin receptor antagonists from Schedule IV to Schedule V under the Controlled Substances Act will reshape compliance obligations for every facility manufacturing, distributing, or storing daridorexant, and Idorsia Ltd is the first sponsor on record to respond. The proposal, expected to publish in the Federal Register on August 11, 2026, opens a 30-day public comment window before any final rule is issued.

The reclassification follows a formal scientific and medical evaluation by HHS, including an eight-factor scheduling analysis, which the DEA then reviewed through its own parallel eight-factor process. The agency's stated basis: DORAs "do not produce physical or psychological dependence", language that carries direct weight for QA directors and regulatory affairs leads managing controlled substance compliance programs under 21 CFR Part 1301.

For plant heads and supply chain operators, the practical read is straightforward. A Schedule V designation carries lighter storage, record-keeping, and DEA production quota requirements than Schedule IV. Facilities currently operating under Schedule IV protocols for daridorexant will need to assess whether existing SOPs, vault specifications, and inventory controls require revision once a final rule is in force, and whether any quota adjustments affect annual manufacturing plans.

Idorsia's interim CEO Jean-Paul Clozel noted the company views Schedule V as "an important first step" while maintaining that available evidence supports full descheduling. Idorsia has indicated it will submit formal comments through the public comment process, a channel equally open to manufacturers, distributors, and other affected stakeholders with compliance data to contribute.

QUVIVIQ (daridorexant) holds FDA approval for adult patients with chronic insomnia characterized by difficulties with sleep onset and/or sleep maintenance; it is the primary DORA product directly implicated by this rulemaking, though the proposed rule applies to the class broadly.

The DEA's final scheduling decision will set the compliance baseline that manufacturers and distributors must meet, making the 30-day comment period the last structured opportunity to place facility-level operational data into the administrative record before that threshold is fixed.

Source: Idorsia Ltd via GlobeNewswire, August 11, 2026.